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ABSTRACT
Objectives: Health-related quality of life (HRQL) instru-
ments generally undergo a rigorous development and val-
idation process. In contrast, methods for interpreting
HRQL data are varied, and no comprehensive widely
applicable procedure exists. Determining whether differ-
ences are statistically signiﬁcant is the most common
method, but this yields conclusions that may be difﬁcult
to understand in a clinical context or which may be of no
practical value. Consequently, there is a need for a com-
prehensive interpretation strategy that gives results
that are meaningful to a variety of audiences, including
patients, clinicians, and decision-makers.
Methods: The review of available interpretation strate-
gies revealed that not all methods are applicable to all
questionnaires, and some strategies may be difﬁcult to
implement for interpreting trial results. In addition, the
issues decision-makers may have when assessing HRQL
results have not really been addressed: what is measured
and what is the meaning beyond statistical signiﬁcance?
Results: A comprehensive stepwise strategy, based on the
most effective methods available, has been developed to
address the key interpretation issues of decision-makers.
It  is  structured  around  several  steps:  understanding
the content of the questionnaire; evaluating the
magnitude of changes and their statistical signiﬁcance;
determining whether results are clinically signiﬁcant, e.g.,
whether the observed changes crossed ranges of estab-
lished threshold for meaningful differences; comparing
pre- and post-treatment scores distribution with norms of
references; and relating score changes to other outcomes
end points such as morbidity, death, compliance, resource
utilization, or productivity.
Conclusions: The proposed strategy should help to struc-
ture and successfully address interpretation issues and
thus make HRQL results more convincing.
Keywords: quality of life, interpretation, clinical signiﬁ-
cance, comprehensive strategy.
Introduction
Health-related quality of life (HRQL) end points
and other patient-reported outcomes (PRO) such as
satisfaction with treatment or symptoms question-
naires are becoming increasingly popular in clinical
trials [1,2] and are being integrated into regulatory
submission packages with increasing frequency. To
be accepted as a scientiﬁc measure, a PRO question-
naire must undergo a validation process to conﬁrm
that  it  is  reliably  measuring  what  it  was  intended
to measure. To be useful to decision-makers, the
results must also be interpreted by attaching clinical
meaning to numerical data. A number of issues
make this a complex task for the decision-maker
and suggest that both researchers and decision-
makers would beneﬁt from supplementing data
with information on interpretation.
Because most instruments have been developed
in the past 10 years, there is a relative lack of data
available for most questionnaires, and the wealth of
experience used in interpreting clinical variables
simply does not exist for HRQL. The Hospital Anx-
iety and Depression scale (HADS) [3] used in
patients with depression and anxiety is a good
example of a questionnaire where clinical experi-
ence supports the interpretation of subjective data
and where score changes can be related to clinically
meaningful differences. In many cases, however,
decision makers will not have had direct experience
with a particular HRQL questionnaire.
The processes for development and validation of
HRQL questionnaires are well deﬁned [4–6]. In
contrast, the interpretation process is not, resulting
in a misconception that HRQL data are less mean-
ingful than traditional efﬁcacy data. At this time,
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interpretation is based primarily on statistical
results, for example, determining whether a differ-
ence between treatment groups is statistically signif-
icant. Nevertheless, because a trivial numerical
difference can become statistically signiﬁcant given
a sufﬁciently large sample, statistical signiﬁcance
alone is insufﬁcient for concluding that HRQL
changed in a meaningful way. In contrast, a mean-
ingful difference may not reach a statistical level of
signiﬁcance owing to insufﬁcient sample size lead-
ing to an increase in the type II error.
Meaningful difference is a subjective concept
that can be approached from several perspectives
[7]. From a patient’s perspective, it may be deﬁned
as the score change that corresponds to a change in
his/her experience of daily life. Decision-makers
might deﬁne a meaningful difference as the small-
est difference in a score that would mandate a
change in the management of the patient [8]. Phy-
sicians may look at individual patient well-being,
treatment success, and prognostic value. Payers
may be most interested in HRQL effects if they
predict changes in medical costs, and health
authorities will be interested in linking results to
resources used, work productivity, and general
health and well-being.
The assessment of HRQL is further complicated
by speciﬁc problems that make the interpretation of
scores more difﬁcult. For example:
• Concepts vary from one questionnaire to
another, even for those targeting the same con-
dition [9]. For example, the Functional Assess-
ment of Cancer Therapy (FACT) [10] and the
European Organization for the Treatment of
Cancer (EORTC) [11] quality-of-life question-
naires are two well-validated and widely used
measures for assessing cancer care. Concepts
covered by the FACT include physical, func-
tional, social, and emotional well-being and
relationship with doctor, whereas the EORTC
QLQ-C30 addresses global quality of life, phys-
ical, role, emotional, social, and cognitive func-
tions and symptoms including nausea and
vomiting, pain, fatigue, dyspnea, sleep distur-
bance, appetite loss, and constipation.
• The scale label does not always reﬂect the exact
content of items in the scale. Moreover, the con-
tent of two similarly named scales may be very
different. For example, the EORTC social func-
tioning scale measures interference with family
life and social activities, whereas the FACT
social well-being scale evaluates family and
friends’ support, family communication, and
acceptance and satisfaction with sex life. Thus,
interpretation cannot be made on the basis of
the scale name alone.
• The number of items and their scaling vary, lead-
ing to differences in anchors, direction, and
magnitude of change. For example, the Notting-
ham Health Proﬁle (NHP) [12] and the SF-36
[13] have both been used in patients with dia-
betes. A score of 0 reﬂects the best HRQL on the
NHP scores, whereas 0 means the worst HRQL
in each dimension of the SF-36. Furthermore, a
10-point change is not the same for both instru-
ments and, even across the SF-36 dimensions, a
10-point change should be interpreted in differ-
ent ways.
Several strategies have been proposed for inter-
preting HRQL scores. These address the meaning of
data in relation to standardized ratios, clinical
parameters, or other external references. Neverthe-
less, they are not always applicable in the context of
a clinical trial or are not relevant for a disease-spe-
ciﬁc questionnaire or are limited to only one partic-
ular aspect. More recently, the clinical signiﬁcance
of quality-of-life measures in cancer patients has
been addressed using a number of speciﬁc perspec-
tives [14]. Sprangers and colleagues [14] have pro-
posed a check list to clinicians for assessing
meaningful changes in HRQL overtime.
So far, however, there is no comprehensive
approach suitable for the interpretation of HRQL
questionnaires and HRQL results from a global per-
spective. Most importantly, the decision-maker’s
point of view, considering results of a study using a
new questionnaire, has not been the central perspec-
tive for interpretation, and the issues he or she may
encounter have not been properly addressed.
The purpose of this review is to identify existing
strategies for the interpretation of generic and dis-
ease-speciﬁc instruments and to devise a strategy
for interpreting HRQL data that can be used
across instruments. In doing this, we have gathered
the experience in interpretation gained to date and
have also considered the issues decision-makers
face in trying to understand and interpret HRQL
data. We have also attempted to address the funda-
mental issue of the criteria for demonstrating clini-
cal signiﬁcance, or “meaningful difference,” in
clinical trials. Speciﬁc issues related to study
design, study quality, or missing data have not
been addressed in this article either because they
were considered nonspeciﬁc to HRQL data or
because speciﬁc publications are available on the
subject [15–17].
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General Strategies for Interpretation of 
HRQL Data
Mandatory Starting Point: A Well-Developed and 
Validated HRQL Instrument
The development and validation of HRQL ques-
tionnaires is fundamental to understanding the con-
tent of a questionnaire and provides a foundation
for interpreting scores. Findings and decisions taken
during the development and validation stages will
impact the interpretation; for example, the number
of hypothesized scales, the names given to scales,
and the scaling of answers. Validation, which can be
regarded as the ﬁrst step toward interpretation [18],
consists of analyzing the construct being measured
and includes the relevance of the scoring system, the
reliability of the scores or measurement error, their
validity, or extent to which scales measure what
they are supposed to measure and their responsive-
ness [19]. Questionnaires frequently need to be
translated into several different languages for use in
international studies and each translation must be
culturally adapted and validated [20,21]. The lin-
guistic validation should be complemented by a
psychometric analysis aimed at demonstrating the
structural and technical equivalence of the trans-
lated versions with the original questionnaire
[22,23].
Although precise knowledge of the content, scor-
ing, reliability, and validity of a questionnaire is a
prerequisite for its interpretation, the information
provided by validation studies is not generally suf-
ﬁcient for a comprehensive and convincing interpre-
tation of HRQL changes [18].
Distribution- and Anchor-Based Interpretation
In their comprehensive review of interpretation
strategies, Lydick and Epstein [7] grouped interpre-
tation methods into two broad categories: distribu-
tion-based and anchor-based interpretation
(Table 1).
Distribution-based strategies use the statistical
distribution of results and are therefore based on
means and standard deviations, statistical tests of
differences or changes over time. Effect size has
become a popular approach [24]. It can be used
to create a picture of the magnitude of changes in
HRQL data and can be used as a benchmark
against which other instruments can be measured.
Scores from the EORTC HRQL questionnaire
QLQ-C30, which assesses HRQL in patients with
cancer, have been interpreted using effect sizes. For
example, an effect size of 0.51 has been reported in
women with metastatic breast cancer feeling a little
better, whereas the effect size was 0.86 in women
feeling very much better. This provides a sense of
the means and differences between different clinical
groups, resulting in a clinical benchmark for inter-
pretation [25]. Other potential forms of distribu-
tion-based interpretation [26] shown in Table 1 do
not appear to be very popular in HRQL research.
Anchor-based strategies relate—or anchor—
HRQL levels or changes to clinical status or to
other meaningful criteria such as life events or a glo-
bal rating. Retrospective patient or clinician assess-
ment of change in status falls into this category.
Other examples of anchor-based interpretation are
shown in Table 1. Most relevant approaches of
anchor-based interpretation are presented in the
“speciﬁc interpretation strategies” section. Lydick
and Epstein [7] concluded that anchor-based inter-
pretations were more likely to be relevant to clini-
cians than distribution-based strategies.
Content-, Construct-, Criterion-, and 
Norm-Based Interpretation
In developing the Medical Outcomes Survey (MOS)
36-item short form (SF-36), a widely used generic
instrument, Ware and colleagues [18,27] used con-
tent-, construct-, norm-, and criterion-based inter-
pretation strategies (Table 2).
Content-based interpretation involves examining
the content of general health measures, using qual-
itative and quantitative descriptions of scales and
their anchors. The content of a question determines
what a respondent thinks as he or she answers the
question and therefore provides information about
what the answer means. While interpretation of
meaning based on the content of the question
is straightforward for single-item measures, it
becomes more complex in multi-item scales. One
approach is to use the percentage of response to one
item as an internal criteria, which is easy to under-
stand in terms of health status, to interpret the
scores across scale levels. For example, in the SF-36,
a representative item within the physical function-
Table 1 Distribution- and anchor-based interpretation
strategies
Distribution-based interpretation Anchor-based interpretation
Statistical signiﬁcance Disease conditions
Effect size Global rating
Reliable change Life events
Proximity to mean Threshold effect
Unit of  change Changes with time





ing scale—the ability to walk one block—was
assessed in a group of respondents who had a phys-
ical function score of 75 and also in those with a
score of 45. It was found that 90% of people with
a score of 75 were able to walk one block without
limitation, but only 32% of those with a score of 45
could walk the same distance. This gives the inves-
tigators the context in which to distinguish between
scores of 75 and 45 [27].
In construct-based interpretation, the relation-
ship between or among scales is examined. Con-
structs are deﬁned as variables that cannot be
directly measured and that are thought to be
responsible for the relationship between measured
variables [28]. Understanding how questionnaire
scale scores relate to underlying health concepts,
how scales relate to other scales within the ques-
tionnaire, and the relationship of scale scores with
scores on other questionnaires can help in inter-
preting the meaning of HRQL scores. A strong
relationship between two sets of scales in a ques-
tionnaire means that they are measuring similar
concepts and that there are probably overlaps in
interpretation. For example, a factor analysis of
the SF-36 revealed two components: one that is
strongly related to the physically oriented scales of
the SF-36, that is, physical function, bodily pain,
and role physical scales, and another that was
related to the mental components [29]. High corre-
lations were observed between the physical, men-
tal, vitality, and pain scales of the SF-36 and the
NHP, indicating that these scales measure similar
concepts [30].
Criterion-based interpretation uses information
about how scale scores relate to external variables
to determine their meaning; these external varia-
bles include clinical or socially meaningful life
events such as job loss, utilization of health-care
services, ability to work, or prediction of mortality.
For example, the physical functioning scale of the
SF-36 has been correlated with a patient’s ability to
work; almost 70% of patients with physical func-
tioning scores of 20 were unable to work, com-
pared with 3% to 6% of patients with physical
functioning scores ≥80 [28]. In light of the rela-
tionship between the scale score range and an
external criterion (ability to work), the social rele-
vance of the physical functioning scale can be more
easily understood.
Norm-based interpretation and known–group
interactions were originally classiﬁed as exam-
ples of criterion-based interpretation [18]. Norm-
based analysis involves calculating scores for a
large population-based sample and using these
norms to examine how the particular group
under study deviates from this expected behav-
ior in this case self-reported HRQL. This method
has been used in interpreting SIP scores [31],
where scores from a population of cardiac-arrest
survivors were compared with those for a healthy
population.
In known–group interactions, the meaning of a
score is understood by referencing scores obtained
in populations differing for known clinical charac-
teristics. Hunt and colleagues [32] used this method
in the interpretation of results from the NHP to




Interpretation is based on characterization
of  the content of  the measure, using a 
speciﬁc item of  a scale as an internal criteria.
To interpret the 36-item short form (SF-36) general health scale, 
ranging from 0 to 100, the percentage of  the general US population
that evaluates their health as excellent, good, fair, or poor has been
described for each category of  scores ranging from 10 to 10 (0 to 
10, 11 to 20, etc.).
Construct-based Based on how scales relate to one another,
to the dimensions they were intended to 
measure, and to other conceptually related 
variables.
Between questionnaires: comparison of  the SF-36 and the 
Nottingham Health Proﬁle (NHP) shows high correlation between
the physical morbidity, pain, mental health, and vitality scales of  
both questionnaires, suggesting that these scales are measuring 
similar concepts.
Within questionnaires: the physical functioning, bodily pain, and 
role physical dimensions of  the SF-36 are highly correlated, 
suggesting that there are some underlying similarities in the 
concepts being measured (physical function).
Norm-based Normative data make it possible to interpret
scale scores by comparison with scores 
for other individuals.
SF-36 scores of  patients with migraine have been compared with 
norm scores to interpret the impact of  migraine. Migraine 
particularly affects the bodily pain and role physical scores.
Criterion-based This strategy relates changes in health-
related quality-of-life (HRQL) scores to 
external variables.
Ability to work and physical functioning: 10 levels of  the physical 
functioning scale of  the SF-36 have been correlated with the 
percentages of  medical outcomes survey (MOS) panel participants 
who said that their health kept them from working. These 
percentages can be used to interpret the physical functioning scale.
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compare patients who consulted their physician
with those who did not consult their physician,
based on the assumption that nonconsulters were
healthier than consulters. Patients who consulted
their physician had consistently higher scores for
every scale in the questionnaire, indicating a worse
HRQL than nonconsulters.
Speciﬁc Interpretation Strategies
Interpretation Based on Life Events
Changes in HRQL scores have been calibrated
against recognized stressful life events to assess the
change in health during clinical studies of antihy-
pertensive drugs. This provides a means of relating
change in HRQL score with easily understood con-
cepts such as moving house, getting divorced, or the
death of a spouse. Testa and colleagues [33] have
used this method to interpret the effects of treat-
ment on the HRQL of men with hypertension over
a 24-week study period. Changes in HRQL were
indexed in a calibration model. The difference in the
overall HRQL scores of 0.22 unit between the treat-
ment groups was considered clinically relevant with
a positive change of 0.11 for one treatment and a
negative change of 0.11 for the other treatment,
corresponding to life events such as major change
in work responsibilities, problems with in-laws, or
mortgage foreclosure. This method has also been
used to deﬁne the threshold for clinically important
changes.
Interpretation Based on Global Rating of  Change
Minimal important difference using a 15-point
intensity scale. A substantial amount of research
has led to the development of the concept of mini-
mal important difference (MID). Jaeschke and col-
leagues [8,34] deﬁned the MID in HRQL scores
as the smallest change in score large enough to
mandate a modiﬁcation of treatment from the
clinician’s perspective and the smallest change
considered important by patients. When clinical
measures are interpreted as part of decision-
making, this concept is often understood intui-
tively, as clinicians use their experience to decide
what is an important change in their patients.
This combination of intuition and experience is
not yet available in the majority of HRQL studies
or instruments; consequently, Jaeschke and col-
leagues have attempted to establish a framework
around which this might develop. Two analyses
were performed: one in patients with heart and
lung disease [8] and the second in patients with a
variety of illnesses [34]. Two very similar HRQL
measures were used: the Chronic Respiratory
Questionnaire (CRQ) [35] and the Chronic Heart
Failure Questionnaire (CHFQ) [36] and, later on,
the Asthma Quality of Life Questionnaire (AQLQ)
[37,38]. In these questionnaires, each item had a
7-point answer scale; for example, the question
that asked “Please indicate how much shortness of
breath you have had during the last 2 weeks while
climbing stairs” had a range of seven answers
from “Extremely short of breath” to “Not at all
short of breath.” A global rating of change, from
-7, a very great deal worse, to +7, a very great
deal better, was used as an anchor to deﬁne small,
medium, and large changes. These changes were
related to the mean change in CRQ, CHFQ,
AQLQ, or subscale scores. Jaeschke and col-
leagues [8,39] only considered a global rating of 0
as no change for their analysis of the CRQ and
CHFQ, whereas Juniper and colleagues [37,38]
lumped 0, -1, and 1 global ratings together to
constitute the “no change” category in their analy-
sis of the AQLQ. Patients felt that a mean change
per item of approximately 0.5 on a 7-point Likert
scale was the minimal change that they perceived
as signiﬁcant, whereas differences of 0.5–1 and >1
were considered moderate and large, respectively
(Table 3).
Anchoring changes using a 5-point distress scale or
a 7-point intensity scale. Anderson [40] has pro-
posed a system for anchoring HRQL scores on a
symptom distress scale in patients with angina. This
involved administering a symptom distress index,
consisting of 73 symptoms that were rated on a
scale of 0 to 5, to measure both how much the
patient suffered from a symptom and how distress-
ing it was. Patient responses were: “did not have the
symptom,” “had it but no distress,” “some dis-
tress,” “moderate distress,” “very much distress,”
and “extreme distress.” These six answers were
simpliﬁed to three distress levels: none, some, and
extreme. Anderson deﬁned ﬁve types of change: a
change from none to extreme (two steps worse);
Table 3 Changes in combined CRQ and CHFQ scores cor-
responding to different global ratings of  change







0 (no change) 0.10 0.12 0.02
1–3 (small change) 0.43 0.64 0.49
4–5 (moderate change) 0.96 0.87 0.81
6–7 (large change) 1.47 0.94 0.86
CRQ, Chronic Respiratory Questionnaire; CHFQ, Chronic Heart Failure
Questionnaire
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none to some and some to extreme (one step worse);
none to none, some to some, and extreme to
extreme (no change); extreme to some and some to
none (one step better); and extreme to none (two
steps better). These changes in symptom distress
could be correlated with changes in the scores of a
coadministered HRQL questionnaire, to increase
the interpretability of the HRQL questionnaire
score. This method has been used to help interpret
the meaning of changes, with 95% conﬁdence inter-
vals, in the Mental Health Index for patients suffer-
ing from hypertension and angina [40].
Osoba and colleagues [26] used effect size related
to a 7-point change subjective signiﬁcance question-
naire (SSQ) in interpreting scores obtained from the
EORTC QLQ-C30 questionnaire. Women with
breast cancer were asked to rate changes in physi-
cal, emotional, and social functioning and global
quality of life after chemotherapy. Patients who
indicated a small change on the SSQ had an increase
or decrease in the range 5 to 10 on the QLQ-C30
questionnaire. The mean change in QLQ-C30 score
for patients who had a moderate change on the SSQ
was in the range 10 to 20 and large changes corre-
lated with a QLQ-C30 score change >20. Effect
sizes increased in agreement with increasing
changes in SSQ and QLQ-C30 scores. In this way,
results from the questionnaire were anchored to
patients’ perception of changes in health status and
patients effectively acted as their own comparison.
Interpretation Based on the Standard Error of  
Measurement (SEM)
Wyrwich and colleagues [41,42] have recently pro-
posed using the one-SEM criterion as a proxy to
evaluate clinically meaningful change. The SEM is
estimated by multiplying the standard deviation of
the scale by the square root of 1 minus its reliability
coefﬁcient [41]. Although the SEM is a distribution-
based statistic evaluating the true score change, the
authors have shown that one-SEM change corre-
sponded well with the patient-driven MID using the
CRQ [8]. The MID and SEM for each scale of the
CRQ (dyspnea, fatigue, and emotional function)
were, respectively, 0.43, 0.64, and 0.49 (MID) and
0.48, 0.53, and 0.41 (SEM). Weighted kappa coef-
ﬁcients between MID and one-SEM of patients clas-
siﬁed as improved, stable, or declined were for each
scale, respectively, 1.00, 0.87, and 0.91 (P < .001
for the three scales). The authors concluded that the
SEM could be a useful tool in establishing the link
between clinically relevant and statistically mean-
ingful intraindividual changes. Results should be
conﬁrmed with other instruments.
Determining Threshold Scores Using a 4-Point 
Bother Scale
The American Urological Association has devel-
oped a symptom index for use in patients with
benign prostatic hyperplasia (BPH) [43,44]. The
scaling of the 7 items of this index ranged from 0 to
5. The authors used a global distress question:
“Overall, how bothersome has any of your trouble
with urination been in the last month (not at all, a
little, some, a lot)?” to determine threshold values
in a cross-sectional design. This method permits cat-
egorization of patients who completed the question-
naire once, into three groups according to symptom
severity. The summated scores generated by the 7
items of this index range from 0 to 35; patients with
scores from 0 to 7 were classiﬁed as having mild
symptoms, those with scores from 8 to 19 were
classed as moderate, and patients with scores of 20
were considered to have severe symptoms. This
index has subsequently been used in the validation
of the USA–Spanish version of the SF-36 in a
Cuban-American population with BPH [45].
Examples of Interpretation for 
Existing Instruments
To illustrate the issues in interpretation of HRQL
results, a review of the literature was undertaken to
identify the approaches that have been used in inter-
preting a range of key questionnaires. These include
the SF-36, SIP, and NHP, all generic instruments
widely used in clinical trials and the EORTC QLQ-
C30, the FACT, and the AQLQ, a speciﬁc question-
naire. The SF-36 has undergone the most extensive
interpretation, based on numerous studies of
norms, including general populations in the United
States [27,29,46] and extensive validation in many
countries [47–49] and speciﬁc statistical techniques
like receiver operating characteristics (ROC)
[50,51]. Two user manuals are also available for
this questionnaire [27,29].
The SIP has also undergone content-based inter-
pretation and clinical interpretation based on
known groups [52], as well as extensive statistical
interpretation, including effect size, MID based on
patient satisfaction, and ROC [53]. A user manual
and interpretation guide is available [52]. The
development and the international validation of the
NHP has led to the development of a European
guide [54] including norms and known groups
comparison.
The cancer-speciﬁc EORTC QLQ-C30 question-
naire has undergone clinical interpretation based on
14 published studies [25]. Effect size interpretation
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has also been used [25,26]. Norwegian general pop-
ulation norms [55] and norms for Danish women
[56] have been generated for use in interpretation.
Other strategies used have mainly centered on cri-
teria, including the MID [26] and a comparison of
patient and observer ratings [57].
The FACT-G questionnaire has been interpreted
based on the initial validation data used as reference
[58] and, more recently, using the global rating
of change to determine meaningful change for
improvement or worsening [59]. A user manual is
available for this questionnaire [60]. The clinically
meaningful change of the FACT-L (lung) has been
determined using a range of criteria such as per-
formance status rating, weight loss, presence of pri-
mary disease symptoms, change over time related to
disease progression, SEM, and effect size [61].
Interpretation of the AQLQ has been somewhat
more limited and has concentrated on MID in a lim-
ited number of patients [38], with instability of the
results according to the wording of the global ques-
tion used [62]. A user manual is available for this
questionnaire.
Although several methods have been used in the
interpretation of some of the above-mentioned
questionnaires, there is a scarcity of information on
the comparability of the results obtained using dif-
ferent methods. In a recent literature review, Samsa
and colleagues [63] noted similarities between clin-
ical signiﬁcance benchmarks of HRQL scores as
determined by Cohen’s standard effect sizes, and
results from explicit anchor-based methods. In their
own pilot study, the clinical signiﬁcance of Health
Utilities Index (HUI) scores was determined using
the general health domain of the SF-36 and the SIP-
total as external anchors. Similar HUI benchmarks
(MIDs) were obtained using the distribution-based
(effect size) method and anchor-based (SF-36 gen-
eral health/SIP-total) method. More recently, Cella
and colleagues [61] found concordant results using
clinical or distribution methods to determine the
clinically meaningful change of the FACT-L.
Proposed Stepwise Interpretation Strategy
The overview of the issues associated with interpre-
tation of HRQL data revealed not only the diversity
of methods available, but also the absence of a
standardized procedure suitable for a variety of
instruments or adapted to the interpretation of clin-
ical trial results. This research has led us to formu-
late recommendations for a comprehensive strategy
useful across instruments and studies. The proposed
interpretation strategy comprises ﬁve main steps,
each of them addressing a speciﬁc point correspond-
ing to major issues decision-makers may encounter
when assessing HRQL results. Each step provides a
speciﬁc set of information that is complementary to
the others:
• Full description of the content of the scale and
its psychometric properties.
• Evaluation of the magnitude of the change or
difference and its statistical signiﬁcance.
• Comparison of observed changes with estab-
lished meaningful magnitudes of changes or
score calibration.
• Comparison of the baseline/follow-up scores
with norms or available known-group
references.
• Determination of the practical value of scores.
The different steps that should ideally be under-
taken to generate the relevant data for each ques-
tionnaire are presented below with the speciﬁc
points related to the interpretation of the results of
a particular study. Knowledge of the content of the
scale and its psychometric properties can be seen as
a basic background for interpretation. The second
step, dealing with statistical signiﬁcance, is also
mandatory to begin interpretation. These two steps
should be supplemented by at least one of the
remaining three steps to determine the clinical sig-
niﬁcance, based on either comparison of scores with
meaningful change, comparison with norms and
known-group references, or other methods to deter-
mine the practical or predictive value of the scores.
In practice, it may be difﬁcult to generate the level
of information required for each step. The proposed
steps should be seen as a strategy to accumulate evi-
dence for demonstrating the meaningfulness of
results. The higher the level of evidence, the more
convincing the results. In Table 4, we have summa-
rized these steps and the strategy that can be fol-
lowed to interpret study results.
Content of  the Scale and Its Psychometric Properties
This step should provide a clear and precise
description of what is measured by a scale at the
item level, including the meaning of the lowest and
the highest possible scores. General wording like
“social functioning” is not sufﬁciently informative
to describe the content of a scale. This step, very
often missing in the interpretation, may encompass
the content criterion proposed by Ware [27] for
interpreting the SF-36, but at the very least requires
detailed description of the meaning of items and
the underlying constructs being measured. Reliabil-
ity and validity data should be provided to under-
Marquis et al.100
stand the homogeneity of the scale, its stability
over time, and its relationships with other related
constructs.
Magnitude of  Changes and Statistical Signiﬁcance
This component looks at the statistical signiﬁcance
of differences and aims to produce a directly inter-
pretable description of the magnitude of changes.
This is based on standardized ratios generating a
common reference for the interpretation of changes,
thereby avoiding the problem of distribution, or
standard deviation, which varies from one scale to
another. Effect size and standardized response mean
are typical examples of useful statistics that may be
generated. These ratios are used to evaluate the
responsiveness of the instruments during psycho-
metric validation. Most of the distribution-based
strategies described by Lydick and Epstein [7] are
included in this category.
Meaningful Change and Score Calibration
The determination of the MID and—probably in
the future—the SEM, or the development of a score
calibration are essential. Nevertheless, no consensus
has yet been reached concerning the best way to
determine the MID. Conceptual and practical difﬁ-
culties regarding the use of retrospective patient glo-
bal assessment have been discussed [62,64–66]; in
particular, the paradox resulting from the use of a
single, nonvalidated item to calibrate a validated
multi-item questionnaire. Currently, the global rat-
ing of change or the subjective perceived change
scales are the most commonly used methods to inte-
grate the patient perspective. Keeping in mind the
Table 4 Proposed stepwise comprehensive strategy for interpretation of  a new speciﬁc questionnaire and study results
Steps
Initial development of  instruments and further
use in observational/epidemiologic studies Interpretation of  study results
Two mandatory steps:
1. Understanding the content of  the scale and its psychometric properties
• Describe the content of  the scale at item level, 
including the meaning of  the lowest and highest 
possible scores and range of  well-being.
• Provide reliability coefﬁcient and construct 
validity evidence.
• Acquire knowledge of  the scale
content and psychometric properties.
2. Evaluation of  the magnitude of  the change or of  the difference and its statistical signiﬁcance
• Calculate ES or SRM related to meaningful
clinical changes to demonstrate the
responsiveness of  the scale.
• Calculate ES or SRM related to treatment 
effect and interpret them using existing criteria.
Supplemented by at least one of  the following steps to determine the clinical signiﬁcance:
3. Comparison of  changes with established thresholds for meaningful magnitudes of  changes or score calibration
• Determine MID, SEM, or score calibration using
global rating of  change or distress scale, for example, or using 
a clinical anchor if  relevant.
• Compare within-group changes to ranges of  
MID, SEM, or score calibration.
4. Comparison of  the baseline/follow-up scores with norms or available known-group references
• Collect data in different relevant clinical severity
groups and in nonsymptomatic patients or
general population if  relevant.
• Provide full distribution for each group,
including conﬁdence intervals and percentage 
at ﬂoor and ceiling.
• Interpret baseline distribution according to 
references or norms.
• Determine percentage of  patients already in 
the well-being range at baseline using 
distribution parameters; relevant clinical groups
used as references chosen according to the 
condition and the availability of  meaningful 
clinical indicators.
• Interpret distribution over time and end point 
distribution according to references or norms.
5. Understanding the practical values of  scores
• Collect data using relevant parameters 
retrospectively or prospectively. Structure 
around three sets of  criteria: morbidity and 
death, patient behavior (compliance and resource 
utilization), and consequences on work (loss of  
productivity or working days).
• Describe the association of  scale score ranges 
with the proposed set of  criteria (e.g., percentage 
able to walk, number of  treatments, treatment
failure, visits to clinicians, days out of  work).
• Describe the predictive value of  scores and 
their changes for the same set of  criteria.
• Interpret changes with available parameters 
such as morbidity, patient behavior in terms of  
compliance or resource utilization, and
consequences on work (productivity, days out
of  work).
• Estimate NNT, when relevant, according to 
ranges of  meaningful changes (i.e., ranges of  
MID), or to the number of  patients having 
reached the expected level of  well-being or 
normative level of  functioning.
ES, effect size; SRM, standardized response mean; NNT, number needed to treat; MID, minimally important difference; SEM, standard error of  measurement.
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need for further research, the use of ranges of MID,
with conﬁdence intervals, for example, is recom-
mended to express thresholds. Other methods
should be considered using clinical anchors
[66,67,68] or other types of patient-reported out-
comes (satisfaction with care [53] or comparative
rating, for example [69]). The usefulness of the
SEM should be further considered as a criterion for
evaluating minimum important change.
One must remember that the MID is determined
within a group and not between groups; for exam-
ple, its use is relevant to interpret changes from
baseline in each treatment group of a trial, but it
should be used with care when comparing differ-
ences in change between treatment groups or in
groups with noticeable differences in disease or
sociodemographic characteristics.
References or Norms
Use of references or norms provides a distribution
of scale scores in reference groups, such as the
general population, or a population without any
known disease [70]. In the case of a speciﬁc ques-
tionnaire, reference scores in the general population
may be difﬁcult to obtain and it may be necessary to
use data from cured patients or patients without
symptoms as references. Other known groups may
include patients with a recognized and relevant clin-
ical status.
Practical Value
This ﬁnal component is often of greatest interest to
clinicians and other interested parties as it relates
HRQL data to practical variables, leading to con-
crete implications. This is the method in which
a researcher might predict other outcomes for
patients with a given HRQL score. Different out-
comes can be used, such as the association with or
the prediction of 1) morbidity (clinical status,
relapses) and death; 2) patient behavior in terms of
compliance and resource utilization (need for treat-
ment, level of treatments needed, adherence, treat-
ment switches, physician contacts, hospital stays,
need for assistance); and 3) loss of productivity and
days out of work.
Ware’s criterion-based interpretation strategy,
the number of patients who beneﬁt from treatment
and the number needed to treat (NNT), all fall in
this category. The NNT can be calculated using the
number of patients having reached the expected
level of well-being or functioning derived from a
reference population or the number of patients
whose HRQL score has increased by a certain size
judged to be clinically signiﬁcant [71,72]. Indeed,
this part is the most difﬁcult to achieve because the
amount of data required is high. Furthermore, there
is a risk that emphasizing this criterion for interpre-
tation minimizes the perceptions of the patient,
whose condition is really the matter of interest.
Conclusions
Potential users of HRQL questionnaires are at the
beginning of a lengthy learning process, which can
be accelerated if instrument developers provide
thorough documentation on the instruments pro-
duced. This information should have educational,
convincing, and demonstrative values. Therefore, it
should be relevant to the audience, based on known
parameters, and structured around a standardized
interpretation protocol. When practical constraints
make it impossible to address the perspectives of all
decision-makers, the challenge is to identify the pri-
mary audience and then determine which interpre-
tation strategies are both feasible and relevant for
addressing the needs of that audience [73].
One must keep in mind that the issues faced in
the interpretation of HRQL data are issues that
have also been encountered historically in clinical
assessment. Only with time, experience, and data
are clinical assessments standardized, modiﬁed, or
rejected.
Our recommendation is that a user manual,
which would include interpretation guidelines com-
posed of different approaches, should accompany
the development and validation of a questionnaire.
The objective is to accumulate evidence to help
decision-makers assess the usefulness and the mean-
ing of study results. We recommend that interpre-
tation include content, psychometric, and statistical
signiﬁcance information as well as at least one of
the ﬁnal three steps—meaningful change, refer-
ences, or practical value. This involves the planning
of interpretation perspectives from the beginning of
the development of the questionnaire and also dur-
ing the analysis and reporting of studies.
This study was supported ﬁnancially by Mapi Values.
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